KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.
Despite growing regulatory acceptance, widespread adoption of NAMs depends on workflow integration, reproducibility, and perceived risk in industry decision-making.
New findings suggest that the location of mRNA expression in the body plays a critical role in shaping T cell responses, opening the door to more precise and effective mRNA-based treatments.